齐拉西酮治疗难治性精神分裂症的疗效分析

目的探讨齐拉西酮治疗难治性精神分裂症患者的疗效和安全性。方法对60例难治性精神分裂症患者换用齐拉西酮进行治疗,疗程16周。在治疗前、治疗后2、4、8、12、16周用阳性症状与阴性症状量表(PANSS)、不良反应症状量表(TESS)评价其疗效和副反应。结果经齐拉西酮治疗后PANSS总分与治疗前比较有显著性差异(P<0.01),阳性、阴性和一般精神病理症状量表评分比治疗前减低(P<0.05)。结论齐拉西酮对难治性精神分裂症疗效肯定,安全性高。

A control study of Ziprasidone in the treatment of refractory schizophrenia

Objective To explore the efficacy and safety Ziprasidone in the treatment of refractory schizophrenia.Methods 60 refractory schizophrenics were instead of treated with Ziprasidone for 16 weeks.Clinical efficacies were assessed with the Positive and Negative Symptoms Scale(PANSS)and adverse effects with the Treatment Emergent Symptom Scale(TESS).Results After treatment,PANSS total score after treatment and before treatment there were significant differences(P<0.01),positive,negative and general spirit of pathological symptoms Scale score lower than before treatment(P<0.05).Conclusion Ziprasidone is a safety and effective antipsychotic and has higher safety and well compliance in refractory schizophrenics.